SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival

0476783 - ÚEM 2018 RIV GB eng J - Článek v odborném periodiku
Mohelníková-Duchoňová, B. - Strouhal, O. - Hughes, D. J. - Holcatová, I. - Oliverius, M. - Kala, Z. - Campa, D. - Rizzato, C. - Canzian, F. - Pezzilli, R. - Talar-Wojnarowska, R. - Malecka-Panas, E. - Sperti, C. - Federico Zambon, C. - Pedrazzoli, S. - Fogar, P. - Milanetto, A.C. - Capurso, G. - Fave, G.D. - Valente, R. - Gazouli, M. - Malleo, G. - Lawlor, R.T. - Strobel, O. - Hackert, T. - Giese, N. - Vodička, Pavel - Vodičková, Ludmila - Landi, S. - Tavano, F. - Gioffreda, D. - Piepoli, A. - Pazienza, V. - Mambrini, A. - Pedata, M. - Cantore, M. - Bambi, F. - Ermini, S. - Funel, N. - Lemstrová, R. - Souček, P.
SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival.
Scientific Reports. Roč. 7, MAR 2017 (2017), s. 43812. ISSN 2045-2322. E-ISSN 2045-2322
Grant CEP: GA ČR(CZ) GAP301/12/1734
Institucionální podpora: RVO:68378041
Klíčová slova: genome-wide association * genetic susceptibility * loci * transporters
Obor OECD: Biochemistry and molecular biology
Impakt faktor: 4.122, rok: 2017

Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging the SLC22A3 gene sequence and regulatory elements were selected for analysis. Of these, 22 were successfully evaluated in the discovery phase while six significant or suggestive variants entered the validation phase, comprising a total study number of 1,518 cases and 3,908 controls. In the discovery phase, rs2504938, rs9364554, and rs2457571 SNPs were significantly associated with pancreatic
Trvalý link: http://hdl.handle.net/11104/0273216